Visit our website

UcCol Duo

Improve your intestinal health thanks to UcCol Duo

An innovative dual-release product for managing and controlling all types of IBD symptoms

IBD: An Overview of Its Prevalence, Pathophysiology, and Management Strategies

Inflammatory bowel disease (IBD) results from the interaction between genetic and environmental factors which influence the immune responses. Inflammatory bowel diseases are mainly divided into ulcerative colitis (UC) and Crohn’s disease (CD). Crohn’s disease is similar to UC, both of which have been classified as chronic IBD and which cause digestive disorders and inflammation in the gastrointestinal tract. Some of the symptoms of CD and UC include diarrhea, abdominal pain, rectal bleeding, and weight loss. They are mainly characterized by inflammation. Both the diseases may occur in adolescents and adults and affect men and women equally.
In 2023, the global prevalence of inflammatory bowel disease (IBD) was estimated to exceed 7 million cases, and both incidence and prevalence continue to rise worldwide. The increasing burden is attributed to complex interactions between genetic susceptibility, environmental influences, and lifestyle changes that affect the gut microbiome. IBD typically presents as a chronic, relapsing condition that significantly impacts patients’ quality of life and poses growing challenges for healthcare systems worldwide.

UcCol Duo: Innovation in Digestive Health

UcCol Duo offers a unique and effective solution, providing strong support for gut health and UC symptom management.

  • Innovative double-release technology (first portion of intestine - last portion of intestine). Guaranteed protection and bioavailability of the synbiotic (prebiotic and probiotic), thanks to the cap-in-cap (CIC) system.
  • The first CIC product on the market to manage/control UC symptoms.
  • A complete formula that offers a synergistic effect.
  • Rebalance the gut microbiota thanks to the synbiotic.
  • Scientifically supported. High-quality, clinically tested ingredients.

Innovative Double-Release Technology

UcCol Duo’s unique dual-capsule system ensures precise delivery, directly targeting the specific site of the disease for optimal effectiveness.

  • EXTERNAL CAPSULE
    Intestinal absorption of the components: Boswellia serrata is absorbed in the intestine primarily through passive diffusion, but its poor water solubility limits bioavailability.
    Co-administration with black pepper can enhance absorption, as it increases solubility and improves absorption.

    COMPOSITION

    • Black pepper
    • Boswellia serrata
    • Vitamin D
    • Vitamin B12
  • INTERNAL CAPSULE
    Internal capsule that releases its ingredients after the external capsule has dissolved, targeting the last portion of the intestine.

    Probiotic protected from interactions with components of the inner capsule to guarantee stability of the synbiotic.
    The synbiotic corrects the gut microbiota imbalance (dysbiosis). Directly delivered at the intestine to colonize the gut.

    COMPOSITION

    Synbiotic:

    • Bifidobacterium longum
    • Saccharomyces boulardii
    • FOS
  • The design is based on innovative double-release technology, ensuring both capsules open in the intestine to precisely target the site of the disease.

Improve your intestinal health with clinically proven studies

Objetive

A randomized, double-blind, placebo-controlled trial was conducted to investigate the efficacy of B. longum supplementation for inducing remission in patients with active UC.

Results:

  • Rectal bleeding score significantly decreased in the B. longum group.
  • No significant decrease in the placebo group.
  • Patients receiving B. longum had a significant reduction in mucosal findings compared to the placebo group.

Objetive

A clinical study was conducted to evaluate the efficacy of S. boulardii in UC patients.

  • Study Details:

    • Group: 24 patients with mild to moderate clinical flare-up of UC.
    • Treatment: Additional S. boulardii for 4 weeks during maintenance treatment with mesalazine.

Results:

  • All 24 patients completed the 4-week course and reported no side effects.
  • A significant reduction in the clinical index score was observed at the end of treatment.
  • Successful outcome achieved in 17 patients (68% of cases).
  • In all instances, sigmoidoscopy confirmed the clinical remission.

Everything You Need to Know to Improve Your Gut Health

UcCol Duo is an innovative dual-release product designed for managing and controlling all types of UC symptoms.

UcCol Duo is indicated for patients with UC:

Stand-alone treatment for patients in the remission phase.
Coadjuvant treatment alongside standard therapy.

UcCol Duo is a food supplement developed with an exclusive formula based on bioactive compounds from natural sources, probiotics, and vitamins. Its components work synergistically to help reduce inflammation in the intestinal tract, improve gut barrier function, and modulate intestinal permeability.
  • Stand-alone/coadjuvant treatment during remission phase: 1 cap/day

  • A probiotic is a live microorganism that, when administered in adequate amounts, provides health benefits to the host.

  • A prebiotic is an ingredient that is selectively utilized by host microorganisms and confers beneficial health effects. Prebiotics serve as food for the beneficial microorganisms that inhabit our bodies.

  • According to the available technical information, the ingredients in UcCol Duo are well tolerated and do not have side effects at the recommended doses. If you are pregnant or breastfeeding, consult your doctor before using this product.

About Aora Health

Nutraceutical Research and Development Company

We are part of AORA Health, a nutraceutical research and development company.

We create innovative, scientifically proven solutions with specific benefits designed to complement or replace pharmaceuticals.

Our mission is to improve people’s well-being through nutraceutical products with proven benefits and the backing of science.